echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Nature Medicine: Plasma phosphorylated tau protein combined with simple cognitive tests and APOE genotyping can improve the predictive ability of Alzheimer's dementia

    Nature Medicine: Plasma phosphorylated tau protein combined with simple cognitive tests and APOE genotyping can improve the predictive ability of Alzheimer's dementia

    • Last Update: 2021-06-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The combination of plasma phosphorylated- tau (P-tau) protein and other available biomarkers may provide accurate Alzheimer's disease (AD) dementia risk prediction.


    The combination of plasma phosphorylated- tau (P-tau) protein and other available biomarkers may provide accurate Alzheimer's disease (AD) dementia risk prediction.


    Sebastian Palmqvist et al .


    The registration flow chart of BioFINDER samples.


    The registration flow chart of BioFINDER samples.


    Model selection process and performance for predicting AD dementia within 4 years.


    Model selection process and performance for predicting AD dementia within 4 years.


    Comparison with clinically predicted AD dementia within 4 years

    Comparison with clinically predicted AD dementia within 4 years

    The model selection and performance of ADNI predicting AD dementia within 4 years were compared with the model selected in BioFINDER.


    The model selection and performance of ADNI predicting AD dementia within 4 years were compared with the model selected in BioFINDER.


    Cross validation and algorithm implementation.


    Cross validation and algorithm implementation.


    The study carried out plasma P-tau , plasma Aβ42/Aβ40 , plasma neurofilament light chain, APOE genotype, simple cognitive test and AD- specific magnetic resonance imaging measurement.


    4 years, plasma in plasma P-tau217 P-tau217 in the BioFINDER BioFINDER accurately predicted accurately predicted the AD ( (the AD area under the curve area under the curve (the AUC) = 0.


    In summary, the plasma in plasma P of tau- P of tau- binding simple cognitive tests and binding simple cognitive tests and the APOE the APOE genotyping may significantly improve genotyping may significantly improve the AD the AD of the diagnostic prediction of diagnostic prediction , Diagnose and promote the recruitment of AD trials.


    Original source

    Palmqvist, S.


    Palmqvist, S.
    , Tideman, P.
    , Cullen, N.
    et al.
    Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures.
    Nat Med(2021).
    https://doi.
    org/10.
    1038/ Z-s41591-021-01348 the Palmqvist, S.
    , Tideman, P.
    , Cullen, N.
    et Al.
    Nat Med

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.